ARRIVENT BIOPHARMA, INC. Investment Income, Interest
ARRIVENT BIOPHARMA, INC. (AVBP) reported Investment Income, Interest of $3.67 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-14.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2024-11-14
- ARRIVENT BIOPHARMA, INC. investment income, interest for the quarter ending 2024-09-30 was $3.67M, a 58.44% increase year-over-year.
- ARRIVENT BIOPHARMA, INC. investment income, interest for the quarter ending 2024-06-30 was $3.82M, a 275.91% increase year-over-year.
- ARRIVENT BIOPHARMA, INC. investment income, interest for the quarter ending 2024-03-31 was $3.26M.
- ARRIVENT BIOPHARMA, INC. investment income, interest for the quarter ending 2023-09-30 was $2.31M.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month |
|---|---|---|---|
| 2024-09-30 | $3.67M 10-Q · filed 2024-11-14 | $7.49M derived: sum of 2 quarters · filed 2024-11-14 | $10.75M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $3.82M 10-Q · filed 2024-08-14 | $7.08M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $3.26M 10-Q · filed 2024-05-08 | ||
| 2023-09-30 | $2.31M 10-Q · filed 2024-11-14 | $3.33M derived: sum of 2 quarters · filed 2024-11-14 | $3.33M 10-Q · filed 2024-11-14 |
| 2023-06-30 | $1.02M 10-Q · filed 2024-08-14 | $1.02M 10-Q · filed 2024-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |